Results 51 to 60 of about 5,279 (205)
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 SOMALI"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins
ChemMedChem, Volume 21, Issue 19, 14 October 2026.Viral proteins represent key vulnerabilities in human coronaviruses (HCoVs). This review outlines inhibitors targeting spike (S), main protease (Mpro), papain‐like protease (PLpro), and RNA‐dependent RNA polymerase (RdRp), mapping chemically diverse strategies that disrupt entry and replication, and provides an integrated view of current candidates ...
Álvaro de la Cruz‐Potenciano +3 more
wiley +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 HMONG"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
The Use of Paxlovid Amongst the Elderly & Reduced Hospital Stays [PDF]
, 2023 Coronaviruses are a large family of viruses infecting many species and cause a variety of illnesses. COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2).
Gichana, Maria M +3 more
core
Fact sheet for Paxlovid. Chinese
, 2021 Title from PDF caption (viewed on January 3, 2022)."OHA4029E12292021 SIMPLIFIED CHINESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core +1 more source
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Advances in Respiratory MedicineNirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj +1 more source
Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors
ChemMedChem, Volume 21, Issue 19, 14 October 2026.We designed, synthesised, and evaluated new guanidine derivatives as potential covalent inhibitors of TMPRSS2, a key protease for SARS‐CoV‐2 entry. Computational studies showed that some compounds have improved binding over nafamostat. However, experimentally none effectively blocked viral entry in cell assays, indicating further optimisation is needed.
Marco Minneci +6 more
wiley +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 PORTUGUESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
BMC MedicineBackground Paxlovid has been shown to be effective in reducing mortality and hospitalization rates in patients with coronavirus disease 2019 (COVID-19).
Weijie Wang +5 more
doaj +1 more source
Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
BioMed Research International, 2022 In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of off‐target and in vivo immune profiles are reported. Various drugs and novel compound candidates for the treatment of the COVID‐19 pandemic have been developed.
Mahrokh Marzi +3 more
openaire +2 more sources